SI-BONE, Inc. (SIBN) SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
SI-BONE, Inc. NASDAQ:SIBN Healthcare · Medical - Devices
Mkt Cap $951.5M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026
SI-BONE will participate in the UBS Global Healthcare Conference in Palm Beach Gardens, FL.
Management will host a fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. Pacific / 5:00 p.m. Eastern, with a live webcast available and replay archived for at least 90 days.
The release contains no financial results or guidance; it is a scheduling notice only.
• 3d ago AI analysis › Press Release
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SI-BONE will report Q3 2026 financial results after market close on Monday, November 2, 2026.
Management will host a conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern, with a webcast archived for at least 90 days.
This is a scheduling notice only; no financial results or guidance are included.
• 13d ago AI analysis › Press Release ⚠ 1
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
SI-BONE received FDA 510(k) clearance for the iFuse Granite Onyx System, its first product intended for use outside the pelvis.
Onyx targets screw loosening at the upper and lower instrumented vertebrae in spinal fusion constructs, a problem affecting up to 27% of fusions, particularly in patients with low bone density.
It is SI-BONE's third breakthrough-designated platform, expanding the 3D-printed bone integration market opportunity to spinal fusion and a broader surgeon base.
• 1mo ago AI analysis › Press Release
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SI-BONE announced that management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York.
The company is scheduled to host a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time.
Investors can access a live audio webcast of the presentation via the company's website, with a replay available for at least 90 days.
• 2mo ago AI analysis › Press Release ● Major
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
SI-BONE reported Q2 2026 revenue of $56.0 million, up 15.2% year-over-year, driven by a 19% increase in its active U.S. physician base.
The company achieved positive adjusted EBITDA of $2.8 million, a 178% improvement, and raised its full-year 2026 revenue guidance to $231 million to $233 million.
Operational milestones include the CMS finalization of higher payments for complex spinal fusion using iFuse Bedrock Granite and the submission of a 510(k) for a third breakthrough device.
• 2mo ago AI analysis › Press Release
SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SI-BONE announced it will report its second quarter 2026 financial results after the market closes on Monday, August 3, 2026.
Management will host a conference call to discuss the results at 1:30 p.m. Pacific Time, with live and archived audio available on the company's website.
• 3mo ago AI analysis › Press Release ● Critical
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
globenewswire.com • 3mo ago Press Release
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE announced that management will participate in the 2026 Truist Securities MedTech Conference in Boston on June 16, 2026.
The company will host a fireside chat at 8:40 a.m. Eastern Time, accessible via webcast and archived on its investor relations website.
SI-BONE specializes in procedural solutions for compromised bone, focusing on the spinopelvic anatomy.
• 4mo ago AI analysis › Press Release ● Major
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
SI-BONE reported Q1 2026 worldwide revenue of $52.6 million, up 11.2% year-over-year, with U.S. revenue growing 10.0% to $49.3 million.
The company's net loss improved by 33.8% to $4.3 million, or $0.10 per diluted share, from $6.5 million, or $0.15 per diluted share, in the prior year.
Adjusted EBITDA was $2.5 million, a significant improvement from $0.5 million in the corresponding period in 2025.
SI-BONE raised its 2026 revenue guidance to $230 million to $233 million, implying year-over-year growth of 14% to 16%, up from the prior range of $228.5 million to $232.5 million.
• 5mo ago AI analysis › Press Release
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
globenewswire.com • 6mo ago Press Release ● Major
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
globenewswire.com • 6mo ago 
